Personalis (NASDAQ:PSNL) Given New $9.00 Price Target at Morgan Stanley

Personalis (NASDAQ:PSNL) had its price objective lifted by analysts at Morgan Stanley from $5.00 to $9.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s price objective suggests a potential upside of 7.86% from the company’s current price.

Several other research firms also recently weighed in on PSNL. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Wednesday, October 8th. Lake Street Capital reissued a “buy” rating and issued a $11.00 target price on shares of Personalis in a report on Wednesday, November 5th. Needham & Company LLC upped their price target on shares of Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. HC Wainwright raised their price objective on shares of Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Finally, BTIG Research upped their target price on shares of Personalis from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Personalis has a consensus rating of “Moderate Buy” and a consensus price target of $10.29.

Personalis Trading Down 3.3%

Shares of PSNL stock traded down $0.29 on Tuesday, reaching $8.34. 490,338 shares of the stock were exchanged, compared to its average volume of 1,095,969. Personalis has a twelve month low of $2.83 and a twelve month high of $10.95. The company has a market capitalization of $740.95 million, a price-to-earnings ratio of -9.49 and a beta of 1.92. The business’s 50 day moving average price is $7.41 and its 200 day moving average price is $6.12.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The company had revenue of $14.50 million for the quarter, compared to analysts’ expectations of $13.31 million. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts forecast that Personalis will post -1.4 earnings per share for the current year.

Insider Activity at Personalis

In other Personalis news, CEO Christopher M. Hall sold 29,612 shares of the stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $8.99, for a total transaction of $266,211.88. Following the transaction, the chief executive officer directly owned 148,486 shares of the company’s stock, valued at $1,334,889.14. This represents a 16.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 3.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Personalis

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc acquired a new stake in Personalis in the 2nd quarter valued at $30,000. Ameritas Investment Partners Inc. bought a new stake in shares of Personalis in the 2nd quarter worth about $34,000. BNP Paribas Financial Markets grew its holdings in shares of Personalis by 406.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after purchasing an additional 5,177 shares during the last quarter. Focus Partners Wealth bought a new position in Personalis during the 1st quarter valued at about $47,000. Finally, Alpha Wealth Funds LLC bought a new position in Personalis during the 2nd quarter valued at about $66,000. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.